Page 15 - Lobe Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The Investor Summit: Lobe Sciences Invites You to Join Us at the Q2 Virtual Investor Summit Location About Lobe Sciences Lobe is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness. For further information: About the Investor Summit The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting ...

Psychedelic-assisted therapy is seeing rapid innovation and investors are taking note as Lobe Sciences (CSE:LOBE, OTC Pink:GTSIF) emerges with new funding, research and development, according to an article published in the Financial Post.  Psychedelic-assisted therapy is seeing rapid innovation and investors are taking note as Lobe Sciences (CSE:LOBE, OTC Pink:GTSIF) emerges with new funding, research and development, according to an article published in the Financial Post.  Based on the article, mental illness is one of the most challenging public health issues facing the global community....

CEO Presenting on the Emerging Growth Conference on April 14; Register now 04/12/2021 | 06:00am EDT Send by mail : Message : Required fields MIAMI, April 12, 2021 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies announces the Schedule of the 5 th Emerging Growth Conference. EmergingGrowth.com is proud to present and welcome you to the 5 th Emerging Growth Conference. The Emerging Growth Conference identifies companies in a wide range of growth sectors,...

MindMed (OTCQB:MMEDF) released its full-year 2020 financial results.  The company posted a net and comprehensive loss of $35.1 million for the year ended Dec. 31, 2020. Its total assets at the end of the reporting period were $85.6 million, counting $80.1 million in cash. The company used $24.2 million of net cash in operating activities in 2020. Its cash balance as of Tuesday last week hovered at $161 million. The company plans to use the money to improve its portfolio and develop its technology sector. On Monday, MindMed also revealed the results of a study on personalized MDMA dosing, con...

Significant Progress Made as Numinus-Sponsored PRIME Study on Psilocybin-Assisted Psychotherapy for Opioid, Stimulant and/or Alcohol Use Disorders Enters Pre-Implementation Stage Numinus Wellness (OTC:LKYSD) and  Syreon Corporation, a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. The study will contribu...